Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung  Adi F. Gazdar, MD, Trisha K. Savage, MS, Jane.

Published byMeredith Harper Modified over 6 years ago

Similar presentations

Presentation on theme: "The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung  Adi F. Gazdar, MD, Trisha K. Savage, MS, Jane."— Presentation transcript:

1 The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung  Adi F. Gazdar, MD, Trisha K. Savage, MS, Jane E. Johnson, PhD, Anton Berns, PhD, Julien Sage, PhD, R. Ilona Linnoila, MD, David MacPherson, PhD, David G. McFadden, MD, PhD, Anna Farago, MD, PhD, Tyler Jacks, PhD, William D. Travis, MD, Elisabeth Brambilla, MD  Journal of Thoracic Oncology  Volume 10, Issue 4, Pages (April 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 SCLC tumors. A and C, Berns laboratory, (p53/Rb1 double CKO); B and D, Sage laboratory, (p53/Rb/p130 triple CKO). A, Whole lung section demonstrating multiple in situ lesions arising in large airways and a few small invasive carcinomas. Bar 10 microns. B, SCLC with area of necrosis and Azzopardi effect adjacent to a focus of LCNEC. C, High power view of SCLC morphology. D, Combined SCLC carcinoma, with focal areas of poorly differentiated NSCLC. NSCLC, non–small-cell lung carcinoma; SCLC, small-cell lung carcinoma. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Metastases from SCLC. In all models examined, the metastatic tumors usually had SCLC morphology irrespective of the GEMM or the dominant pulmonary tumor phenotype. A and C, Berns laboratory, (B) Sage laboratory, (D) Jacks laboratory (p53/Rb1/Pten triple CKO). A, Extensive mediastinal spread, modest intrapulmonary tumor. B, Intrapulmonary perivascular lymphatic spread with focal invasion of BV wall. C, Metastasis to mediastinal node. D, Metastases to liver. Horizontal bars Distance in microns as indicated. SCLC, small-cell lung carcinoma; GEMM, genetically engineered mouse model; BV, blood vessel. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 LCNECs. A and B, Johnson laboratory; (C and D) Sage laboratory (both laboratories used the same p53/Rb1/p130 triple CKO). A, Intrabronchial in situ lesion with underlying invasive component. B, A lesion similar to the one illustrated in A, CGRP immunostain. Strong cytoplasmic expression of the NE cell product CGRP in both the in situ and invasive tumor components. C, High power view of LCNEC morphology. D, Both LCNEC (left field) to SCLC (right field) morphologies are present within a single lesion. SCLC, small-cell lung carcinoma; NE, neuroendocrine; LCNEC, large-cell NE cell carcinoma. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 NSCLC tumors. A and B, Johnson laboratory; (C and D) MacPherson laboratory (p53/Rb1/PTEN triple CKO). A and B, Adjacent LCNEC (left field) and NSCLC (right field) tumors in the p130 triple knockout model. CGRP immunostaining (B) is limited to the LCNEC tumor and an adjacent NEB within a bronchus separating the two tumors. C and D, In situ SCLC and adjacent invasive NSCLC-NE arising in a Ptenlox/+ triple knockout mouse. CGRP immunostaining (D) demonstrates that the NE cell marker expression is limited to the in situ SCLC component and to a NEB in the same bronchus. NSCLC, non–small-cell lung carcinoma; SCLC, small-cell lung carcinoma; NE, neuroendocrine; LCNEC, large-cell NE cell carcinoma; NSCLC-NE, NSCLC with NE features; NEB, neuroepithelial body. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 NSCLCs with expression of NE cell markers (NSCLC-NE). A and B, MacPherson Laboratory; (C and D) Linnoila laboratory (SV40/ASCL1 driven by CC10 promoter). A, Adenocarcinoma. B, Same tumor as A immunostained for CGRP expression. C and D, Poorly differentiated NSCLC immunostained for Cgrp (C) or Ascl1 (D). There is focal and variable NE marker expression in the tumor. Immunostaining of the foci of NE cell hyperplasia in adjacent bronchi show more intense and uniform expression of Ascl1. NSCLC, non–small-cell lung carcinoma; NE, neuroendocrine; NSCLC-NE, NSCLC with NE features. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung  Adi F. Gazdar, MD, Trisha K. Savage, MS, Jane."

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Impact of Neuroendocrine Differentiation in Non-small Cell Lung Cancer

Impact of Neuroendocrine Differentiation in Non-small Cell Lung Cancer
Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations  Adi Gazdar, MD, Linda Robinson, MS, Dwight Oliver, MD,

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations  Adi Gazdar, MD, Linda Robinson, MS, Dwight Oliver, MD,
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.
A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.
Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe  Michelle C. Salazar, MD, Joshua E. Rosen, BASc,

Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe  Michelle C. Salazar, MD, Joshua E. Rosen, BASc,
Volume 4, Issue 3, Pages (September 2003)

Volume 4, Issue 3, Pages (September 2003)
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K

Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K
Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas  Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas  Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Opening a Chromatin Gate to Metastasis

Opening a Chromatin Gate to Metastasis
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.
Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Similar presentations

Ads by Google